New incident report
Incident Report Number: 2023-3896
Registrant Reference Number: 3598502
Registrant Name (Full Legal Name no abbreviations): Scotts Canada Ltd.
Address: 2000 Argentia Road - Plaza 2 Suite 300
City: Mississauga
Prov / State: ON
Country: Canada
Postal Code: L5N1V8
Human
Country: CANADA
Prov / State: ONTARIO
PMRA Registration No. 29694 PMRA Submission No. EPA Registration No.
Product Name: SCOTTS WEED B GON MAX RTU 1L/12
Yes
Unknown
Site: Res. - Out Home / Rés - à l'ext.maison
Other
Sex: Female
Age: Unknown / Inconnu
System
Unknown / Inconnu
No
Unknown
Non-occupational
None
Unknown
Unknown / Inconnu
Unknown / Inconnu
5/11/2023 Caller states her step father runs a property. He applied the product outdoors, to the front lawn property to treat dandelions on 5/09/2023. A tenant contacted the caller this morning and stated she is experiencing a reaction while in her home. She is experiencing "difficulty breathing" and feeling sick. It is unknown when the symptoms started and if any therapy has been completed. The tenant lives about 10-15 feet away from the application area and parks her car approximately ten feet from the application area in a driveway. The patient was not near her step father during the application. The caller was not familiar with the patient's past medical history. She believes the patient is in her 60s. 5/12/2023 Attempted call back, and spoke with caller. She thinks the tenant is okay because she has not heard back from her. It is unknown if she was seen or not seen in the emergency room as recommended. The pollen was bad yesterday and caller thinks that was the cause of her symptoms.
Minor
The information contained in this report is based on self-reported statements provided to the registrant during telephone Interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and can not form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.